Analysts have been eager to weigh in on the Healthcare sector with new ratings on Zoetis (ZTS), MacroGenics (MGNX) and Natera (NTRA).
Zoetis (ZTS)
In a report released today, David Risinger from Morgan Stanley maintained a Hold rating on Zoetis, with a price target of $174.00. The company’s shares closed last Friday at $165.90, close to its 52-week high of $176.64.
According to TipRanks.com, Risinger ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -4.2% and a 44.3% success rate. Risinger covers the Healthcare sector, focusing on stocks such as Endo International, Merck & Company, and Perrigo Company.
Currently, the analyst consensus on Zoetis is a Moderate Buy with an average price target of $186.71, implying a 12.8% upside from current levels. In a report issued on November 8, Raymond James also maintained a Hold rating on the stock.
See today’s analyst top recommended stocks >>
MacroGenics (MGNX)
In a report released today, David Lebovitz from Morgan Stanley maintained a Sell rating on MacroGenics, with a price target of $14.00. The company’s shares closed last Friday at $21.65.
According to TipRanks.com, Lebovitz is a 4-star analyst with an average return of 5.9% and a 59.5% success rate. Lebovitz covers the Healthcare sector, focusing on stocks such as Rhythm Pharmaceuticals, Syndax Pharmaceuticals, and Ionis Pharmaceuticals.
MacroGenics has an analyst consensus of Hold, with a price target consensus of $25.50.
Natera (NTRA)
In a report released today, Puneet Souda from Leerink Partners maintained a Buy rating on Natera, with a price target of $95.00. The company’s shares closed last Friday at $83.14, close to its 52-week high of $90.03.
According to TipRanks.com, Souda is a 5-star analyst with an average return of 32.7% and a 79.2% success rate. Souda covers the Healthcare sector, focusing on stocks such as Castle Biosciences, Twist Bioscience, and Exact Sciences.
Natera has an analyst consensus of Strong Buy, with a price target consensus of $91.14, which is an 8.8% upside from current levels. In a report issued on November 6, Canaccord Genuity also maintained a Buy rating on the stock with a $87.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
